Evidence map›Paper›PMID 30154364›Full record

ArticleInternational journal of molecular sciences2018

DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrum-Implications for the Choice of Circulating Tumour DNA Methylation Markers.

Anh Viet-Phuong Le, Marcin Szaumkessel, Tuan Zea Tan, Jean-Paul Thiery, Erik W Thompson, Alexander Dobrovic

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Potential Role ofClinical Medicine Insights. Oncology · 2024
    Article
  4. Article
  5. Article
  6. Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021
    Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Anh Viet-Phuong LeOlivia Newton John Cancer Research Institute, Heidelberg, VIC 3084, Australia. anh.vple@gmail.com.
Marcin SzaumkesselOlivia Newton John Cancer Research Institute, Heidelberg, VIC 3084, Australia. Marcin.Szaumkessel@onjcri.org.au.
Tuan Zea TanCancer Science Institute of Singapore, 14 Medical Drive, National University of Singapore, Singapore 117599, Singapore. csittz@nus.edu.sg.
Jean-Paul ThieryCancer Science Institute of Singapore, 14 Medical Drive, National University of Singapore, Singapore 117599, Singapore. bchtjp@nus.edu.sg.
Erik W ThompsonDepartment of Surgery, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC 3065, Australia. e2.thompson@qut.edu.a.
Alexander DobrovicOlivia Newton John Cancer Research Institute, Heidelberg, VIC 3084, Australia. alex.dobrovic@onjcri.org.au.ORCID 0000-0003-3414-112X
The University of Melbourne · AUNational University of Singapore · SGOlivia Newton-John Cancer Wellness & Research Centre · AUTranslational Research Institute · AUUniversité Paris-Sud · FR

Funding

National Breast Cancer Foundation CG10-04, CG12-07, PS-15-048,
6 · The paper itself

Abstract

(1) Background: Epithelial⁻mesenchymal plasticity (EMP) is a dynamic process whereby epithelial carcinoma cells reversibly acquire morphological and invasive characteristics typical of mesenchymal cells. Identifying the methylation differences between epithelial and mesenchymal states may assist in the identification of optimal DNA methylation biomarkers for the blood-based monitoring of cancer. (2) Methods: Methylation-sensitive high-resolution melting (MS-HRM) was used to examine the promoter methylation status of a panel of established and novel markers in a range of breast cancer cell lines spanning the epithelial⁻mesenchymal spectrum. Pyrosequencing was used to validate the MS-HRM results. (3) Results:

Indexed as

Biomarkers, TumorCirculating Tumor DNADNA MethylationBreast NeoplasmsCell Line, TumorCpG IslandsEpigenesis, GeneticEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansPromoter Regions, GeneticBiomarkers, TumorCirculating Tumor DNAbiomarkersbreast cancercirculating tumour DNADNA methylationepithelial–mesenchymal plasticitymethylation-sensitive high-resolution melting (MS-HRM), pyrosequencingminimal residual disease

Identifiers

PMID30154364
PMCPMC6164039
OpenAlexW2901724267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.